CClinicalTrials.gg
RecruitingNCT06871995Updated Mar 12, 2025

Efficacy, Safety and Limitations of Spinal Block for All Infants Under 3 Months

An interventional study of spinal block in Anesthesia, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 1 Day to 3 Months. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
1 Day to 3 Months
Sex
All
01

Study summary

Spinal anesthesia (SA) has been shown to be a viable alternative to general anesthesia (GA) for infants and children for a variety of surgical procedures. SA serves to avoid some of the potential risks of GA including the need for airway manipulation, hemodynamic instability, postoperative apnea, and exposure to medications that may cause neurotoxicity .SA allows the prevention and reduction of perioperative complications even if its duration is an important limiting factor. Because of this limitation, short surgery is the most indicated under SA . Premature infants and neurologically impaired children account for the majority of spinal anesthetics used today .

This study evaluates the effectiveness, safety and limitations of spinal anesthesia when used for all infants under 3 months undergoing lower abdominal surgery at Ain Shams University Hospitals.

Read the detailed description

Patients will be carefully examined 24 hours (h) to the procedure and every case will be assessed individually concerning its eligibility for spinal anesthesia under the supervision of a senior pediatric anesthesiologist. History taking and clinical examination along with the necessary laboratory tests . Standard blood test is cbc and we will use it a routine before surgery. About 1 ml blood is needed as a sample.

Counseling the parents or the legal guardian regarding every aspect of the procedure and obtaining their informed written consent.

All patients will be fasting from formula milk for 6 hours, breast milk for 4 hours and clear fluid for 1 h before anesthesia . No overnight premedication will be given.

After the establishment of intravenous access, all patients will be given crystalloid solution (Ringer's solution or Normal Saline) of 10 ml/kg over 30 minutes started with the application of monitors. Heart rate, blood pressure, oxygen saturation. Blood glucose level is measured.

The monitors will be connected and pulse oximetry (SPO2) baseline non-invasive blood pressure (NIBP), heart rate (HR), and electrocardiogram (ECG tracings) will be obtained. Fluid bolus of 5 ml/kg will be used for any intraoperative hypotension. Atropine 50µ/kg will be given intravenously if HR dropped > 20% of baseline reading . Intraoperative blood loss will be replaced by 3 times volume with the same crystalloid .blood glucose level is measured after injection then every 30 minutes till end of surgery .

All patients will receive spinal anesthesia via midline approach with patients in sitting position established by assistant under complete aseptic conditions. A subcutaneous bleb using Lidocaine 1% through the needle of an insulin syringe followed by minor skin scratch to will help avoiding possible intrathecal dermoid implantation . A lumbar puncture will be performed in L4-L5 or L5- S1 interspace using 25-G 25-mm pencil-point spinal needle . Depth of epidural space is anticipated at 0.1 mm/kg . After getting free flow of cerebrospinal fluid (CSF) hyperbaric bupivacaine (0.5%) in a dose of 0.5 mg/kg (0.1 ml/kg) will be slowly injected in the subarachnoid space . The end of the injection will be taken as time zero for further data recording.

Since the Bromage score is not assessable among this pediatric population, the success of the spinal anesthesia is estimated and based on the presence of profound motor block (unable to move feet, knees and legs) in the lower extremities and the absence of a skin prick response using toothed forceps at the appropriate dermatome level. If these signs will not confirmed after 5 min, general anesthesia will be performed . All of these cases will be registered as spinal block failure Then pacifier dipped with sugar water will be offered to the baby.

Throughout the operation, the effect of the spinal anesthesia will be monitored till return of spontaneous movement or response to surgical stimulus then sevoflurane mask will be applied and surgery continues either mask or even intubation then mean time of conversion to general anesthesia will be recorded and registered as spinal block failure.

Complications from SA:

Hypotension is defined as a more than 20%decrease in mean blood pressure from baseline. (Mean blood pressure =post conceptual age in weeks ).

Bradycardia is defined as a heart rate less than 120 b/min or HR dropped > 20% of baseline reading) Apnea is defined as a sustained respiratory pause of 15 s or longer or less than15s if accompanied by oxygen saturation (SpO2) less than 90% or bradycardia. Hypoxemia is defined as oxygen saturation below 90% .

High spinal block is defined as apnea after spinal injection without sedative drugs and/or motor block of the upper extremities and no response to hand finger pinprick All this complications will be monitored intra and postoperatively and managed accordingly.

All patients will be admitted postoperative for 12 hours in the hospital. Post operative cbc also a routine blood test will be done .The conductors of this study will record the degree of motor block and pain. The pain control will be measured using the Face, Legs, Activity, Crying, and Controllability (FLACC) pain score (0-10 score range) . The FLACC score will be evaluated and recorded during the first 12h immediately postoperative and at 2, 4, 6, 12 hours postoperatively. The time of giving analgesia (intravenous paracetamol 15 mg/kg) will be recorded when the FLACC score exceeds 4, with a maximum of four doses per day, and total paracetamol consumption will be recorded . It is given that pain medications will be given when the FLACC score exceeds 4 at assessment or in between of the allotted time interval.

02

Conditions studied

  • Anesthesia
03

In context

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 3 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age under 3 months.
  • Physical status: American Society of Anesthesiologists I - II.
  • Elective lower abdominal surgeries such as: hernia, hydrocele, undescended testis

Exclusion criteria

Exclusion Criteria:

  • Patient's parents or legal guardian refusing to do this specific procedure.
  • Coagulopathy, use of anti-coagulant or antiplatelet therapy.
  • Infection at the site of injection.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    one arm All Infants Under 3 Months of Age receiving Spinal Block

    All Infants Under 3 Months of Age Scheduled for Lower Abdominal Surgery

    Procedure: spinal block

Interventions

  • Procedurespinal block

    All patients will receive spinal anesthesia via midline approach with patients in sitting position established by assistant under complete aseptic conditions. A subcutaneous bleb using Lidocaine 1% through the needle of an insulin syringe followed by minor skin scratch to will help avoiding possible intrathecal dermoid implantation . A lumbar puncture will be performed in L4-L5 or L5- S1 interspace using 25-G 25-mm pencil-point spinal needle . Depth of epidural space is anticipated at 0.1 mm/kg . After getting free flow of cerebrospinal fluid (CSF) hyperbaric bupivacaine (0.5%) in a dose of 0.5 mg/kg (0.1 ml/kg) will be slowly injected in the subarachnoid space . The end of the injection will be taken as time zero for further data recording.

06

What researchers measure

Primary outcomes

  1. the success rate of spinal block in abdominal surgeries in infants under 3 months of age.

    Success rate = (no of total patients - no of all converted general anesthesia patients) divided by no of total cases%.

    Time frame: during the surgery

Secondary outcomes

  1. Duration of spinal block in minutes

    Duration of spinal block

    Time frame: during the surgery

  2. Number of attempts

    Number of attempts till success

    Time frame: during the surgery

  3. Depth of insertion of the spinal needle

    from skin to subarachnoid space

    Time frame: during the surgery

  4. Blood glucose level

    sample to measure blood glucose

    Time frame: every 30 minutes till end of surgery

  5. Determine the incidence of complications

    1. Apnea that will be considered as high spinal block 2. Hypotension (a more than 20% decrease in systolic blood pressure from baseline.) 3. Bradycardia (a heart rate less than120 /min or HR dropped \> 20% of baseline reading) 4. Hypoxemia (oxygen saturation below 90%) .

    Time frame: after spinal block to end of surgery

07

Study locations

1 of 1 sites recruiting
  • Faculty of Medicine Ain Shams University
    Cairo, Egypt
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06871995
Lead sponsor
Ain Shams University
Responsible party
Sponsor
First posted
Mar 12, 2025
Start date
Mar 2025 (estimated)
Primary completion
Jun 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
Mar 12, 2025

Study contacts

ahmed ma Elewa mohamed, M.S.C
Contact
AhmedElfax@med.asu.edu.eg
+201028143995
tarek Sa Shabana, MD
Contact
Tarek.shabana@hotmail.com
01001594109
hany mo Elzahaby, prof
study director · Ain Shams University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion